Wellington Management Group LLP Reduces Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Wellington Management Group LLP trimmed its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 80.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 119,293 shares of the biotechnology company’s stock after selling 478,935 shares during the period. Wellington Management Group LLP owned 0.05% of ADMA Biologics worth $2,385,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the stock. Quest Partners LLC bought a new stake in ADMA Biologics during the second quarter valued at about $29,000. Hollencrest Capital Management bought a new position in shares of ADMA Biologics during the 3rd quarter valued at approximately $30,000. Larson Financial Group LLC purchased a new stake in ADMA Biologics in the 3rd quarter worth approximately $31,000. Harvest Fund Management Co. Ltd bought a new stake in ADMA Biologics during the 3rd quarter worth approximately $62,000. Finally, Acadian Asset Management LLC purchased a new position in ADMA Biologics during the second quarter valued at approximately $93,000. 75.68% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on ADMA shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $20.00 price target on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright lifted their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Finally, Raymond James boosted their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a report on Friday, November 8th.

Insider Buying and Selling

In other ADMA Biologics news, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at $4,218,007.95. This trade represents a 7.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 3.70% of the stock is currently owned by company insiders.

ADMA Biologics Trading Down 1.8 %

Shares of ADMA Biologics stock opened at $18.63 on Wednesday. ADMA Biologics, Inc. has a twelve month low of $4.06 and a twelve month high of $23.64. The company has a quick ratio of 3.26, a current ratio of 7.09 and a debt-to-equity ratio of 0.48. The business has a 50-day moving average price of $19.00 and a 200-day moving average price of $16.16. The firm has a market cap of $4.40 billion, a price-to-earnings ratio of 67.32 and a beta of 0.70.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. During the same quarter last year, the business posted $0.01 EPS. Equities research analysts anticipate that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.